Song Wen1, Danlin Gu, Hui Zeng. 1. Department of Interventional Treatment, Zhejiang Cancer Hospital, Hangzhou 310006, China.
Abstract
PURPOSE: Liver cancer is one of the major causes of cancer related deaths throughout the world and the fifth most common type of malignancy in men and eighth in women. Beta-amyrin has been reported to exhibit significant pharmacological properties and in the present study we examined the anticancer and apoptotic effects of beta-amyrin against Hep-G2 liver cancer cells. METHODS: The antiproliferative activity of beta-amyrin was determined by MTT assay. Apoptosis was assessed by DAPI staining and DNA damage was checked by the comet assay. The cell cycle analysis was carried out by flow cytometry and protein expression was examined by western blotting. RESULTS: Beta-amyrin exhibited significant anticancer activity against Hep-G2 cancer with IC50 values of 25 μM. The anticancer effects were attributed to induction of apoptosis and G2/M cycle arrest in a dose-dependent manner. Moreover, beta-amyrin could also activate the p38 and JNK signalling pathways. CONCLUSION: Based on the results of the current study, we propose that beta-amyrin may prove an important lead molecule for the treatment of liver cancer.
PURPOSE:Liver cancer is one of the major causes of cancer related deaths throughout the world and the fifth most common type of malignancy in men and eighth in women. Beta-amyrin has been reported to exhibit significant pharmacological properties and in the present study we examined the anticancer and apoptotic effects of beta-amyrin against Hep-G2 liver cancer cells. METHODS: The antiproliferative activity of beta-amyrin was determined by MTT assay. Apoptosis was assessed by DAPI staining and DNA damage was checked by the comet assay. The cell cycle analysis was carried out by flow cytometry and protein expression was examined by western blotting. RESULTS:Beta-amyrin exhibited significant anticancer activity against Hep-G2 cancer with IC50 values of 25 μM. The anticancer effects were attributed to induction of apoptosis and G2/M cycle arrest in a dose-dependent manner. Moreover, beta-amyrin could also activate the p38 and JNK signalling pathways. CONCLUSION: Based on the results of the current study, we propose that beta-amyrin may prove an important lead molecule for the treatment of liver cancer.
Authors: Josianne Rocha Barboza; Francisco Assis Nascimento Pereira; Renan Amphilophio Fernandes; Cleydlenne Costa Vasconcelos; Maria do Socorro de Sousa Cartágenes; Alberto Jorge Oliveira Lopes; Andreia Cristina de Melo; Isabella Dos Santos Guimarães; Cláudia Quintino da Rocha; Maria Nilce de Sousa Ribeiro Journal: Biology (Basel) Date: 2020-09-15